Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sophoridine is a naturally occurring quinolizidine alkaloid primarily extracted from plants of the genus Sophora. It exhibits a broad spectrum of pharmacological activities, notably anti-cancer, anti-inflammatory, antiviral, analgesic, neuroprotective, and cardiovascular-protective effects. Mechanistically, sophoridine acts on multiple molecular pathways, including inhibition of the PI3K/Akt, NF-κB, VEGFR2, TLR4/MyD88/NF-κB, RAS/MEK/ERK, PTEN, and MAPK pathways, among others. It is approved in China for the treatment of several cancers, such as gastric, lung, and liver cancers. Sophoridine is primarily administered by injection in clinical settings, enabling rapid systemic exposure and precise dosing. It has also demonstrated various activities in vitro and in vivo, including the modulation of cytokines and reduction of inflammatory markers, as well as the regulation of cell survival and apoptosis pathways[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sophoridine.